Literature DB >> 23264802

Treatment for Uterine Fibroids: Searching for Effective Drug Therapies.

Darlene K Taylor1, Phyllis C Leppert.   

Abstract

Uterine fibroids are common reproductive-age benign tumors that contribute to severe morbidity and infertility. Cumulative incidence is 4 times higher in Africian-Americans compared to Caucasians and constitutes a major health disparity challenge. Fibroids are the leading indication for hysterectomy and their management averages $21 billion annually in the US. No long term minimally invasive therapies exist. Thus, promising drug therapies, their chemistry, pharmacology, and clinical efficacy, focusing first on innovative drug delivery approaches, are reviewed.

Entities:  

Year:  2012        PMID: 23264802      PMCID: PMC3525705          DOI: 10.1016/j.ddstr.2012.06.001

Source DB:  PubMed          Journal:  Drug Discov Today Ther Strateg        ISSN: 1740-6773


  38 in total

Review 1.  Contraceptives with novel benefits.

Authors:  Ying Su; Qing-Quan Lian; Ren-Shan Ge
Journal:  Expert Opin Investig Drugs       Date:  2011-12-08       Impact factor: 6.206

2.  CDB-4124 does not cause apoptosis in cultured fibroid cells.

Authors:  Hilary Roeder; Friederike Jayes; Liping Feng; Phyllis C Leppert
Journal:  Reprod Sci       Date:  2011-03-21       Impact factor: 3.060

3.  Term myometrium is characterized by increased activating epigenetic modifications at the progesterone receptor-A promoter.

Authors:  S Y Chai; R Smith; T Zakar; C Mitchell; G Madsen
Journal:  Mol Hum Reprod       Date:  2012-02-27       Impact factor: 4.025

4.  Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety.

Authors:  Philippe Bouchard; Nathalie Chabbert-Buffet; Bart C J M Fauser
Journal:  Fertil Steril       Date:  2011-09-23       Impact factor: 7.329

5.  Characterization of tissue biomechanics and mechanical signaling in uterine leiomyoma.

Authors:  John M Norian; Carter M Owen; Juan Taboas; Casey Korecki; Rocky Tuan; Minnie Malik; William H Catherino; James H Segars
Journal:  Matrix Biol       Date:  2011-09-24       Impact factor: 11.583

Review 6.  The impact of uterine leiomyomas on reproductive outcomes.

Authors:  H Cook; M Ezzati; J H Segars; K McCarthy
Journal:  Minerva Ginecol       Date:  2010-06

7.  Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study.

Authors:  Lynnette K Nieman; Wendy Blocker; Tonja Nansel; Sheila Mahoney; James Reynolds; Diana Blithe; Robert Wesley; Alicia Armstrong
Journal:  Fertil Steril       Date:  2010-11-05       Impact factor: 7.329

8.  Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women.

Authors:  Minnie Malik; John Norian; Desirée McCarthy-Keith; Joy Britten; William H Catherino
Journal:  Semin Reprod Med       Date:  2010-04-22       Impact factor: 1.303

9.  The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells.

Authors:  Meagan M Grudzien; Philip Steven Low; Peter C Manning; Melissa Arredondo; Robert J Belton; Romana A Nowak
Journal:  Fertil Steril       Date:  2009-01-09       Impact factor: 7.329

Review 10.  Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS).

Authors:  Oskari Heikinheimo; Kristina Gemzell-Danielsson
Journal:  Acta Obstet Gynecol Scand       Date:  2011-11-09       Impact factor: 3.636

View more
  8 in total

1.  Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations.

Authors:  James H Segars; Estella C Parrott; Joan D Nagel; Xiaoxiao Catherine Guo; Xiaohua Gao; Linda S Birnbaum; Vivian W Pinn; Darlene Dixon
Journal:  Hum Reprod Update       Date:  2014-01-08       Impact factor: 15.610

2.  Injectable Clostridium histolyticum collagenase as a potential treatment for uterine fibroids.

Authors:  Lisa N Brunengraber; Friederike L Jayes; Phyllis C Leppert
Journal:  Reprod Sci       Date:  2014-10-20       Impact factor: 3.060

Review 3.  Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids.

Authors:  Mohamed Ali; Mohamed Raslan; Michał Ciebiera; Kornelia Zaręba; Ayman Al-Hendy
Journal:  Expert Opin Drug Saf       Date:  2021-10-20       Impact factor: 4.250

4.  Leiomyoma cells in 3-dimensional cultures demonstrate an attenuated response to fasudil, a rho-kinase inhibitor, when compared to 2-dimensional cultures.

Authors:  Minnie Malik; Joy Britten; James Segars; William H Catherino
Journal:  Reprod Sci       Date:  2014-08-01       Impact factor: 3.060

5.  Circulating Sex Hormones and Risk of Uterine Fibroids: Study of Women's Health Across the Nation (SWAN).

Authors:  Jason Y Y Wong; Ellen B Gold; Wesley O Johnson; Jennifer S Lee
Journal:  J Clin Endocrinol Metab       Date:  2015-12-15       Impact factor: 5.958

6.  Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids.

Authors:  Md Soriful Islam; Sadia Afrin; Bhuchitra Singh; Friederike L Jayes; Joshua T Brennan; Mostafa A Borahay; Phyllis C Leppert; James H Segars
Journal:  Clin Transl Med       Date:  2021-07

7.  Using rheology to quantify the effects of localized collagenase treatments on uterine fibroid digestion.

Authors:  Ria D Corder; Sashi V Gadi; Robert B Vachieri; Friederike L Jayes; John M Cullen; Saad A Khan; Darlene K Taylor
Journal:  Acta Biomater       Date:  2021-08-08       Impact factor: 10.633

Review 8.  Recent scientific advances in leiomyoma (uterine fibroids) research facilitates better understanding and management.

Authors:  Darlene K Taylor; Kristine Holthouser; James H Segars; Phyllis C Leppert
Journal:  F1000Res       Date:  2015-07-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.